IL-31 Antagonist Composition With Extended Dosing for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapeutic methods for atopic dermatitis require frequent administration or hospital visits, posing a burden on patients and lacking an effective dosing regimen.
Innovation Solution
A pharmaceutical composition comprising an IL-31 antagonist administered at specific dosing intervals ranging from 0.1 to 1000 mg/body/2 weeks to 0.01 to 10 mg/kg/8 weeks, providing a more effective dosing regimen for the prevention and treatment of atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic methods (steroids, antihistamines, PUVA therapy) are used for atopic dermatitis, then the disease symptoms can be suppressed, but the treatment requires frequent administration or hospital visits which burdens the patient
Solution Approach 1:
The patent applies periodic action by establishing specific dosing intervals (every 2 weeks to 8 weeks) for IL-31 antagonist administration. This replaces the frequent daily or weekly treatments with scheduled periodic dosing, reducing patient burden while maintaining therapeutic effectiveness through the drug's sustained action during each interval
Solution Approach 2:
The patent changes the dosing parameters by defining specific dosage ranges (0.1 to 1000 mg/body or 0.01 to 10 mg/kg) combined with extended dosing intervals. This parameter optimization allows the IL-31 antagonist to achieve both high reliability in symptom suppression and improved ease of operation through reduced administration frequency
2Reliability
If conventional therapeutic methods are used for atopic dermatitis, then symptoms can be managed, but patients must visit hospitals frequently for PUVA therapy which increases time loss
Solution Approach 1:
The patent enables self-service treatment by providing a pharmaceutical composition that patients can administer themselves at home according to the established dosing schedule. This eliminates the need for frequent hospital visits required by PUVA therapy, reducing time loss while maintaining therapeutic reliability through proper self-administration of the IL-31 antagonist
3Reliability
If frequent medication administration is required for atopic dermatitis, then therapeutic effectiveness can be maintained, but patient compliance decreases due to forgetting to take medicine
Solution Approach 1:
The patent uses periodic action with extended dosing intervals (every 2 weeks to 8 weeks) that naturally improve patient compliance. The less frequent dosing schedule reduces the cognitive burden of remembering medication times while the sustained effectiveness of the IL-31 antagonist during each interval maintains therapeutic reliability, creating a balance between effectiveness and compliance
Data Source
AI summary
In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.